摘要
目的观察应用来氟米特联合激素治疗难治性IgA肾病的疗效和安全性。方法收集2005年4月至2006年5月南方医院肾内科符合条件的13例IgA肾病患者接受来氟米特联合激素治疗,观察治疗前和治疗后2、4、8、12、16、20、24周的相关临床指标变化,并进行评价。结果与加用来氟米特前比,联合治疗后,1、3、6个月24h尿蛋白定量均有下降(P<0.001),血清白蛋白均有升高(P<0.001),血肌酐变化无统计学差异(P>0.05)。不良反应较轻,病人耐受性良好。结论来氟米特联合激素方案可以作为治疗难治性IgA肾病的选择之一,且安全、有效。
Objective To investigate the effects and safety ofleflunomide combined with hormone therapy for refractory IgA nephropathy. Methods Thirteen patients with refractory IgA nephropathy were treated with leflunomide and hormone therapy, and the clinical data were collected and evaluated before and in weeks 2, 4, 8, 12, 16, 20 and 24 during the treatment. Results Leflunomide therapy significantly improved proteinuria （P〈0.001） and increased serum albumin in these patients （P〈0.001） but caused no significant changes in serum creatinine （P〉0.05）. Only mild tolerable adverse effects were observed. Condusion Leflunomide combined with hormone therapy can be one of the safety and effective choices for treatment of refractory IgA nephropathy.
出处
《南方医科大学学报》
CAS
CSCD
北大核心
2007年第6期893-894,899,共3页
Journal of Southern Medical University
关键词
来氟米特
IGA肾病
激素
leflunomide
IgA nephropathy
hormone
therapy
